TMBIM4 and Huntington disease: These studies, the majority of them in HD models, provide insight into its mechanism of action as an S1R agonist, as well as compelling evidence supporting its clinical development [60,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87].